Posts by mahnie

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida

RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: Video 2 Presented on OncologyTube 2023

RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: Video 1 Presented on OncologyTube 2023

RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem™ as a Treatment Option for Locally Advanced Pancreatic Cancer

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer Presented on OncologyTube 2023

Intra-Arterial Gemcitabine vs IV Gemcitabine PK Substudy in Patients with Locally Advanced Pancreatic Cancer Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium

Incidence and Clinical Characteristics of Patients with LAPC and Mesenteric Vein Thrombosis and Current Treatment Paradigm Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium

Toxicity and Efficacy of Stereotactic Body Radiation Therapy vs. Intensity-Modulated Radiation Therapy for the Treatment of Locally Advanced Pancreatic Cancer in a Phase 3 Trial Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium